

## Due to supply shortages, patients shouldn't be started on Wegovy®

Due to supply shortages of Wegovy, we ask that you don't submit prior authorization requests to start patients on new courses of treatment until the manufacturer, Novo Nordisk®, has communicated that they've fully restored supply across all doses.

As an alternative, you can submit a prior authorization request for Saxenda®, which is also manufactured by Novo Nordisk. The criteria for Saxenda is similar to the criteria for Wegovy. You can view the criteria for Saxenda in our [Prior authorization and step therapy coverage criteria](#) document.

As published on the [Updates about Wegovy](#) page of the Novo Nordisk website\*, Novo Nordisk is experiencing issues at the contract manufacturing site for Wegovy, which have resulted in supply shortages.

To enable patients who have already started treatment with Wegovy to continue treatment, Novo Nordisk has asked health care providers not to start new patients on Wegovy. In addition, they've stopped advertising and promoting Wegovy and they've temporarily stopped shipments of the first two dose strengths.

For the latest updates on the Wegovy supply issues, see the [Updates about Wegovy](#) page of the Novo Nordisk website\* or call 1-833-4-WEGOY (1-833-493-4689) and select option 0.

\*Clicking this link means that you're leaving the Blue Cross Blue Shield of Michigan and Blue Care Network website. While we recommend this site, we're not responsible for its content.